stockrow
Friday 6 November 2026
Export AGL’s income statement to Excel — free account
Agilon Health, Inc.
AGL Healthcare Medical Care Facilities
Agilon Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.9 billion, down 2.11% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- +130.8%
- Free cash flow
- +234.4%
- Total debt
- −12.7%
Quarter to September 2026, against a year earlier
108.53
5.24
−4.61%
Follow AGL
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.22 | 0.30 | 0.02 | 0.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
26.80 | (31.25) | 5.53 | (13.88) | |
P/B ratio |
4.76 | 7.87 | 0.72 | 2.25 | |
Price to Tangible BV |
6.05 | 10.70 | 1.10 | 4.67 | |
EV/Sales |
0.18 | 0.26 | (0.02) | 0.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.35 | 0.00 | |
EV/Operating CF |
(249.26) | (21.64) | 2.83 | (0.33) | |
EV/FCF |
(27.74) | (14.75) | 1.66 | (0.23) | |
Quick Ratio |
1.08 | 1.00 | 0.95 | 0.89 | |
Current Ratio |
1.14 | 1.08 | 1.04 | 1.02 | |
Net Debt/EBITDA |
(9.12) | (12.18) | (25.31) | 1.34 | |
Debt/Assets |
1.95% | 1.90% | 2.00% | 2.75% | |
Debt/Equity |
0.11 | 0.13 | 0.17 | 0.28 | |
Asset Turnover |
3.80 | 3.58 | 3.39 | 3.95 | |
Operating CF/Net income |
1.43 | (3.19) | 0.49 | 0.11 | |
Capex/Depreciation |
(0.48) | (0.63) | (0.46) | (1.40) | |
Interest Coverage |
13.82 | 7.32 | 2.21 | (112.95) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
4.42% | 5.92% | 3.82% | 3.83% | |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.04 | 0.05 | |
Share Based Compensation of Revenue |
1.24% | 1.59% | 0.44% | 0.61% | |
Graham Net Nets |
0.09 | 0.03 | (0.02) | (0.17) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.78%) | (13.28%) | (272.44%) | (137.92%) | |
Free Cash Flow Yield |
(2.85%) | (5.92%) | (65.04%) | (52.21%) | |
Revenue per Share |
90.48 | 89.48 | 85.58 | 94.78 | |
Operating CF per Share |
2.97 | (3.43) | 1.43 | (1.24) | |
Capex per Share |
(0.19) | (0.26) | (0.19) | (0.59) | |
Free Cash Flow per Share |
2.78 | (3.69) | 1.24 | (1.83) | |
Cash per Share |
18.56 | 15.40 | 18.25 | 17.22 | |
Shareholders Equity per Share |
16.73 | 13.62 | 10.93 | 7.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.73 | 13.62 | 10.93 | 7.65 | |
Free Cash Flow |
46.62 | (61.60) | 20.60 | (30.29) | |
Working Capital |
166.47 | 106.19 | 48.85 | 20.21 | |
Capital Expenditures |
(3.26) | (4.31) | (3.13) | (9.76) | |
Net Current Asset Value |
115.15 | 54.73 | (2.33) | (47.86) | |
EV/EBIT |
0.00 | 0.00 | 0.32 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
982.14 | 1,053.48 | 1,069.67 | 845.42 | |
Average Payables |
235.74 | 223.41 | 214.59 | 173.91 | |
Average Assets |
1,580.88 | 1,652.12 | 1,718.90 | 1,502.64 | |
Average Common Equity |
293.48 | 318.23 | 340.84 | 298.84 |
Columns are period end dates · fundamentals updated 4 Nov 2026